Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker Corporation (NASDAQ: BRKR) will report its first quarter 2023 financial results on May 4, 2023, before market opening. A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results and current business trends. Investors can listen to the webcast via the company's investor relations website or by phone. Pre-registration is available for the call to streamline entry. A telephone replay of the conference will be accessible from one hour after the call until June 4, 2023, using a specified access code. Bruker continues to focus on enabling scientists to drive advancements and innovations in various scientific fields.
Bruker Corporation recently showcased its latest innovations in NMR spectroscopy at the Experimental Nuclear Magnetic Resonance Conference (ENC 2023). The highlight is the launch of the Ascend Evo 400, a new 400 MHz NMR magnet with a liquid helium hold-time of one year. This advancement reduces ownership costs and enhances operational convenience.
The Ascend Evo 1.0 GHz system, featuring a 65% reduction in liquid helium consumption, is utilized in prestigious labs like the RIKEN Center in Japan. The release also discusses the HelioSmart-R system, which recovers helium gas, and the new Fourier 80 platform for battery and pharmaceutical research.
Bruker emphasizes its commitment to sustainability and advancing cleantech research, highlighting collaborations with key industry players.
Bruker Corporation (Nasdaq: BRKR) has announced its latest innovations in diagnostic solutions at the 33rd European Congress of Clinical Microbiology & Infectious Diseases. Key highlights include:
- MBT Mycobacteria IVD Kit: Optimizes sample preparation for reliable identification of nontuberculous mycobacteria.
- MBT HT Filamentous Fungi IVD Module: Features an extensive fungal library for high identification success rates.
- MBT Compass HT IVD Software: Enhances microbial identification speed with automated self-tuning, analyzing up to 600 samples per hour.
- LiquidArray® Gastrointestinal PCR Panel: Detects 26 pathogens causing gastroenteritis, streamlining workflows for clinical laboratories.
Dr. Wolfgang Pusch noted that these advancements provide valuable solutions for clinical microbiology labs, enhancing pathogen coverage and identification efficiency.
At the AACR Annual Meeting 2023, PreOmics launched a new BeatBox-based FFPE workflow aimed at enhancing tissue proteomics applications. This workflow allows high-throughput processing of up to 96 FFPE samples simultaneously, streamlining protocol by eliminating the need for xylene-based deparaffinization. The BeatBox system ensures fast processing, typically within 10 minutes, with a demonstrated increase in proteomic depth of 14% to 43% compared to traditional methods. Bruker Corporation will co-commercialize this innovative workflow alongside its timsTOF Pro mass spectrometer. With significant time savings and improved reproducibility, this development is poised to facilitate large-scale biobank projects and enhance research efficiency in pathology.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
